EMA Endorses Two Orphans: Roche’s Gazyvaro and PTC’s Translarna
This article was originally published in The Pink Sheet Daily
Executive Summary
Obinutuzumab is recommended for full authorization in chronic lymphocytic leukemia, while the endorsement for PTC’s Duchenne muscular dystrophy drug ataluren is limited to conditional authorization, with a requirement for confirmatory trial data.